Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of paricalcitol soft capsules for secondary hyperparathyroidism in CKD stage 3-4
CTR20252022Phase 3Active
- Sponsor
- Qingdao Guoxin Pharmaceutical
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paricalcitol in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), sponsored by Qingdao Guoxin Pharmaceutical. Started May 2025; status: active.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20252022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252022.